Alec Stranahan
Stock Analyst at B of A Securities
(0.63)
# 3,717
Out of 4,831 analysts
30
Total ratings
35%
Success rate
-31.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $18.05 | +132.69% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $4.16 | +188.46% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $5.40 | +178.04% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $6.33 | +294.94% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $0.78 | +1,305.21% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.33 | +275.94% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.55 | +135.29% | 2 | Nov 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $39.95 | +37.67% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $6.19 | +190.79% | 3 | Jun 14, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $118 → $140 | $134.53 | +4.07% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $8.11 | +418.20% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $33.37 | -82.02% | 2 | Dec 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $60 → $5 | $1.37 | +264.96% | 1 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $46.22 | -2.64% | 1 | Dec 1, 2022 |
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $18.05
Upside: +132.69%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $4.16
Upside: +188.46%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.40
Upside: +178.04%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $6.33
Upside: +294.94%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $0.78
Upside: +1,305.21%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.33
Upside: +275.94%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.55
Upside: +135.29%
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $39.95
Upside: +37.67%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $6.19
Upside: +190.79%
Krystal Biotech
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $134.53
Upside: +4.07%
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $8.11
Upside: +418.20%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $33.37
Upside: -82.02%
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $1.37
Upside: +264.96%
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $46.22
Upside: -2.64%